ArticleFrontiers in oncology2025
Strategy to select nasopharyngeal cancer patients for adaptive radiotherapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- De-escalation of head-and-neck cancer radiotherapy: balancing cure and side effects.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nasopharyngeal cancer (NPC) patients experience significant anatomical changes during radiation treatment (RT). Adaptive radiotherapy (ART) can be initiated in response to specific events or at scheduled intervals during treatment, prompting questions about patient selection, timing, and reliable triggers for re-CT and replanning. This study aimed to develop a method for selecting NPC patients for ART before treatment and identify the optimal timing for its implementation. Materials and methods: We retrospectively evaluated NPC patients treated at University Hospitals Leuven between 2016 and 2023, assessing volumetric changes in the parotid glands, air cavities, maxillary sinuses, and body contour at nasopharyngeal and low-neck levels throughout treatment. Structures were contoured on the initial simulation CT, weekly CBCTs, and final treatment day, resulting in eight measurements per parameter. Body contour changes were evaluated at the nasopharyngeal level (odontoid process) and neck level (lower edge of the third cervical vertebra). Measurements included volume, transverse diameters, and radius angles of 50° and 310°. Kaplan-Meier analysis was used for overall survival (OS) and local control (LC), while longitudinal volumetric data were analyzed with linear mixed models. Continuous variables were dichotomized to create a binary variable, for the purpose to define cut-off values for significant predictive variables. Results: Of the 47 NPC patients analyzed, 2- and 5-year loco-regional control rates were 95%, with overall survival rates of 100% and 93%, respectively. Significant reductions in parotid gland volume and body contour were observed, particularly between weeks 3 and 4. Predictors of parotid gland volume reduction included bulky nodal disease and larger initial parotid volume, with thresholds of 15 mm and 56 cc, respectively. Body contour changes during the fourth week correlated with high N-stage (≥ N3), higher initial BMI (>28 kg/m²), bulky lymph nodes (15 mm), higher initial mean planned dose to the ipsilateral parotid gland (> 31 Gy) and larger initial primary tumor Clinical Target Volume (> 93 cc). Induction chemotherapy was significantly associated with fewer sinonasal air cavity changes than concomitant chemoradiotherapy. Conclusion: It is recommended to re-evaluate the RT plan during the period between fractions 15 and 20 of treatment. Patients treated for NCP could be selected for ART based on the following clinical criteria at diagnosis: N3 or higher classification, presence of a bulky lymph node larger than 15 millimeters, initial BMI exceeding 28 kg/m², mean planned dose to the ipsilateral parotid glands greater than 31 Gy, cumulative volume of the parotid glands greater than 56 cc, high-dose CTV of the primary tumor greater than 93 cc, and receiving RT with no prior induction chemotherapy. Validation of these pre-treatment clinical predictors in a large, prospective dataset is essential before clinical usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.